52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.
Oct 2026· Journal of American Academy of Dermatology· 0 citations
Medicine
TL;DR
Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.
Abstract
Background
Ruxolitinib (selective Janus kinase [JAK]1/JAK2 inhibitor) cream demonstrated efficacy and safety vs vehicle during 8 weeks of continuous use in a phase 3 study of children with atopic dermatitis (AD).
Objective
To evaluate long-term safety (LTS) and disease control with as-needed ruxolitinib cream use in children.
Methods
Children aged 2-11 years with mild-to-moderate AD initially randomized to ruxolitinib cream (0.75% or 1.5%) in the 8-week study continued the same twice-daily (BID) regimen for an additional 44 weeks but only applied cream as needed BID; patients initially on vehicle were rerandomized (1:1) to apply either ruxolitinib cream strength as needed. Safety and disease control were assessed.
Results
No new safety signals emerged among children who applied ruxolitinib cream in the LTS period (N=282). Application site reactions were infrequent (1.1%), and no serious treatment-related adverse events were observed. Among patients initially randomized to ruxolitinib cream (0.75%/1.5%), disease control was maintained to Week 52 (Investigator's Global Assessment score 0/1, 79.5%/72.3%; affected body surface area, 2.0%/1.9%).
Limitations
No vehicle control in LTS period.
Conclusion
Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can significantly impact quality of life. Baricitinib, an oral selective Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in pediatric patients with moderate-to-severe AD...
A. Wollenberg, A. Torrelo, Masanori Ikeda et al.· SKIN The Journal of Cutaneou...· 0 citations
Introduction & Objectives While phase 3 studies established the safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, for treatment of atopic dermatitis (AD) in adults and adolescents,1-3 it is important to evaluate its safety, efficacy, and optimal dosing in the younger pediatric population. START UP is an...
A. Paller, V. Prajapati, Ulrike Blume-Peytavi et al.· SKIN The Journal of Cutaneou...· 0 citations
INTRODUCTION
Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control.
METHODS
This multicenter retrospective analysis of prospectively collected LANDSC...
L. Potestio, M. Bianco, L. Mastorino et al.· Dermatologic Therapy· 0 citations
Chronic hand eczema (CHE) is characterized by persistent or recurrent inflammatory lesions on the hands and wrists. Ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream has demonstrated efficacy in atopic and nonatopic hand eczema. In a phase 2 study in adults with moderate-to-severe nonatopic CHE (NCT05906628), 1.5%...
M. Zirwas, R. Chovatiya, Benjamin D. Ehst et al.· SKIN The Journal of Cutaneou...· 0 citations
Real-world evidence on long-term effectiveness and safety of oral Janus kinase (JAK) inhibitors in atopic dermatitis (AD) remains limited. This study evaluated sustained long-term clinical and patient-reported disease control and safety during continuous treatment with upadacitinib 30 mg or baricitinib 4 mg. This monoc...
F. D'Oria, Costanza Falcidia, Giulio Foggi et al.· Dermatologic Therapy· 0 citations
Data confirm a role for the IFN-γ-CXCL10 axis in vitiligo pathogenesis and suggest that reductions in CXCL10 expression correlate with clinical repigmentation with ruxolitinib cream.
T. Passeron, M. Lebwohl, C. Lynde et al.· Journal of Investigative Der...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.